^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SY-4798

    i
    Other names: SY-4798
    Associations

    News

    Trials
    Company:
    Shouyao Holdings
    Drug class:
    FGFR4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=80, Recruiting, Shouyao Holdings (Beijing) Co. LTD | Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    FGF19 (Fibroblast growth factor 19)
    |
    SY-4798
    over3years
    A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=80, Recruiting, Shouyao Holdings (Beijing) Co. LTD
    New P1 trial
    |
    FGF19 (Fibroblast growth factor 19)
    |
    SY-4798